Once weekly intraperitoneal therapy for gram-positive peritonitis.

Area of Science:

• Nephrology
• Pharmacology
• Infectious Diseases

Background:

• Peritonitis is a common complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
• Effective antibiotic management is crucial for successful treatment and prevention of complications.
• Vancomycin is a key antibiotic used for peritonitis, but optimal dosing in CAPD patients requires study.

Purpose of the Study:

• To evaluate the pharmacokinetics of a novel intraperitoneal (IP) vancomycin dosing regimen in CAPD patients.
• To assess the clinical outcomes and efficacy of this vancomycin regimen in treating peritonitis.

Main Methods:

• Ten CAPD patients with peritonitis received a 30 mg/kg/2 L IP dose of vancomycin once weekly for 3 weeks.
• Serum vancomycin concentrations were monitored over time.
• Pharmacokinetic parameters (absorption, clearance, volume of distribution, half-life) were calculated.
• Clinical outcomes, including cure rates, were assessed.

Main Results:

• Vancomycin demonstrated high absorption (91%) after the first dose, rapidly achieving therapeutic serum concentrations.
• Mean peak serum concentration was 37 ± 8 mcg/mL at 6 hours.
• Slow elimination was observed, with a mean serum half-life of 184 hours.
• A mean serum concentration of 10 ± 4 mcg/mL was maintained at 168 hours.
• 100% clinical cure rate was achieved in patients with uncomplicated gram-positive peritonitis.

Conclusions:

• The studied weekly IP vancomycin dosing regimen is well-absorbed and achieves sustained therapeutic serum concentrations in CAPD patients.
• This regimen resulted in a high cure rate for gram-positive peritonitis, suggesting its potential as an effective alternative treatment.
• Further investigation into this dosing strategy is warranted for managing peritonitis in CAPD populations.